Your session is about to expire
What is Uptravi
SelexipagThe Generic name of this drug
Treatment SummarySelexipag, sold under the brand name Uptravi, is a medication used to treat pulmonary arterial hypertension (PAH). It was approved by the FDA in 2015 and works by increasing the blood vessels that supply blood to the lungs, leading to increased blood flow and reduced pressure. Selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to achieve this effect. It is used to delay the progression of PAH and reduce the risk of hospitalization.
Uptraviis the brand name
Uptravi Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Uptravi
Selexipag
2015
11
Approved as Treatment by the FDA
Selexipag, otherwise known as Uptravi, is approved by the FDA for 1 uses such as Pulmonary Arterial Hypertension .Pulmonary Arterial Hypertension
Helps manage Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Effectiveness
How Uptravi Affects PatientsSelexipag has been tested to make sure it does not have a harmful effect on the heart's rhythm. It has been seen to inhibit platelet aggregation in a laboratory setting, but does not seem to have an effect on platelet aggregation when taken at normal doses.
How Uptravi works in the bodySelexipag is a drug that helps treat pulmonary arterial hypertension. It works by activating a receptor in the lungs that increases production of a molecule called prostacyclin. This molecule has multiple effects, like increasing blood flow, reducing inflammation, and preventing blood clotting. Selexipag is chemically different from prostacyclin itself, and it is also better at activating the receptor. After it is taken in the body, it is broken down into an active metabolite that is even more effective. This metabolite only affects the prostacyclin receptor and has no other effects on the body.
When to interrupt dosage
The proposed dosage of Uptravi is contingent upon the diagnosed condition. The measure additionally fluctuates as per the technique of conveyance (e.g. Tablet, coated - Oral or Tablet, film coated) featured in the accompanying table.Condition
Dosage
Administration
Pulmonary Arterial Hypertension
, 0.2 mg, 0.4 mg, 0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 0.18 mg/mL, 1.8 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution
Warnings
Uptravi has two contraindications, so it should not be employed while suffering from the conditions in the following table.Uptravi ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Common Uptravi Drug Interactions
Drug Name
Risk Level
Description
Amifostine
Major
Selexipag may increase the hypotensive activities of Amifostine.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Selexipag.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Selexipag.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Selexipag.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Selexipag.
Uptravi Toxicity & Overdose RiskPeople with severe kidney problems may have up to 70% more exposure to the drug than those with healthy kidneys.
Uptravi Novel Uses: Which Conditions Have a Clinical Trial Featuring Uptravi?
53 ongoing trials are studying the utility of Uptravi in providing therapeutic benefit for Pulmonary Arterial Hypertension.Condition
Clinical Trials
Trial Phases
Pulmonary Arterial Hypertension
0 Actively Recruiting
Uptravi Reviews: What are patients saying about Uptravi?
5Patient Review
4/14/2021 This medication has been a lifesaver for me. I was taking Opsumit and Adempas, which helped with my breathing, but the pressure in the right side of my heart was still very high. After taking Uptravi 200mcg once daily, my right side blood pressure has returned to normal levels. I'm so grateful for this medication!
4Patient Review
9/9/2017 I started out taking 200 mcg twice a day, and eventually worked up to 1400 mcg twice a day. However, I had to back down to 1200 mcg because of the side effects which include headaches, neck/shoulder/extremity pain, and diarrhea. Even at this lower dosage though, I've found that the drug makes it easier to breathe and gives me more energy and ambition.
3Patient Review
10/3/2016 I started at a lower dose and have slowly been working my way up. I'm currently experiencing some headaches and body aches, but hopefully this will improve as I continue to increase the dosage.
2Patient Review
11/7/2021 They kept upping the dosage each week, and it made me so nauseous that I had to stop taking it. It was a really terrible experience.
1.7Patient Review
4/30/2018 The side effects of this treatment are beyond horrible. The pain is excruciating and feels like my muscles are being slowly pulled apart.
1Patient Review
10/1/2019 Hardly any benefits and many drawbacks. Ifound it difficult to breathe, my body hurt more, and I had less energy.
Patient Q&A Section about uptravi
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What class of drug is UPTRAVI?
"Uptravi is a medication used to treat Pulmonary Arterial Hypertension. Uptravi works by relaxing the blood vessels in your lungs which lowers your blood pressure. Uptravi may be used alone or in combination with other medications."
Answered by AI
What is UPTRAVI used for?
"UPTRAVI® is a prescription medication used to treat pulmonary arterial hypertension (a condition characterized by high blood pressure in the arteries of the lungs). UPTRAVI® can help to slow the progression of the disease and reduce the risk of hospitalization for PAH."
Answered by AI
Does UPTRAVI lower blood pressure?
"This medication lowers blood pressure by widening blood vessels in your lungs. It is used to treat pulmonary arterial hypertension and can help prevent your condition from worsening or reduce your risk of needing to be hospitalized."
Answered by AI
Is UPTRAVI FDA approved?
"- Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved UPTRAVI® (selexipag) for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients."
Answered by AI